
Fulltext:
79592.pdf
Embargo:
until further notice
Size:
82.43Kb
Format:
PDF
Description:
publisher's version
Publication year
2009Source
Aids, 23, 7, (2009), pp. 863-5ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Internal Medicine
Clinical Pharmacy
Pulmonary Diseases
Journal title
Aids
Volume
vol. 23
Issue
iss. 7
Page start
p. 863
Page end
p. 5
Subject
N4i 3: Poverty-related infectious diseases; NCEBP 13: Infectious diseases and international healthAbstract
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.
This item appears in the following Collection(s)
- Academic publications [227942]
- Electronic publications [107434]
- Faculty of Medical Sciences [86237]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.